Therefore, we expect that the Di-peptide-modified ZIF-8 system can be applied to the co-delivery of the androgen receptor siRNA and chemotherapeutic agents, which is an option for the treatment of castration-resistant prostate cancer. Here, AR is linked to prostate cancer.